Stephen From
Chief Executive Officer bei Aruna Bio, Inc.
Profil
Stephen From is currently the Chief Executive Officer at Aruna Bio, Inc. and Chairman at EyeGate Pharma SAS.
Prior to his current positions, he served as the Executive Chairman at Kiora Pharmaceuticals, Inc. from 2005 to 2022.
He also held the position of Head-European Life Sciences at Banc of America Securities LLC.
In addition, he was the Chief Financial Officer at Centelion SAS from 2004 to 2005.
Mr. From received his undergraduate degree from the University of Western Ontario.
Aktive Positionen von Stephen From
Unternehmen | Position | Beginn |
---|---|---|
EyeGate Pharma SAS
EyeGate Pharma SAS Pharmaceuticals: MajorHealth Technology Part of Kiora Pharmaceuticals, Inc., EyeGate Pharma SAS is a clinical-stage specialty pharmaceutical company based in Paris, France. EyeGate's products include pp-001, a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of dihydroorotate dehydrogenase (“dhodh”) with picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with dhodh inhibitors. The French company is also developing ocular bandage gel (“ obg ”), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. OBG, with unique properties that help hydrate and protect the ocular surface, is in clinical evaluation for patients undergoing photorefractive keratectomy (“prk”) surgery for corneal wound repair after refractive surgery and patients with persistent corneal epithelial defects. Founded in 1998, the private company develops and commercializes products for treating ophthalmic diseases. | Chairman | 05.09.2006 |
Aruna Bio, Inc.
Aruna Bio, Inc. Medical/Nursing ServicesHealth Services Aruna Bio, Inc. manufactures and provides neural stem cells. Its products include neuronet pure human neurons screening kit, neuronet pure human neurons discovery kit, co-culture kit hastropro-neuronet, hastropro human astrocytes kit and motor neurons GFP+htscreening kit. The company was founded by James Stice and Steven L. Stice in 2003 and is headquartered in Athens, GA. | Chief Executive Officer | 27.04.2022 |
Ehemalige bekannte Positionen von Stephen From
Unternehmen | Position | Ende |
---|---|---|
KIORA PHARMACEUTICALS, INC. | Chief Executive Officer | 01.02.2021 |
Centelion SAS | Director of Finance/CFO | 01.09.2005 |
Banc of America Securities LLC
Banc of America Securities LLC Investment Banks/BrokersFinance Headquartered in Charlotte, North Carolina, Banc of America Securities (BAS) is the investment banking subsidiary of Bank of America Corp (NYSE: BAC). The firm provides both the domestic and international equity and investment banking markets, and pursues a strategy pioneered by Citigroup that combines corporate lending with investment banking advice and services. They provide high-yield debt underwriting and leveraged finance, in addition to industry coverage groups such as healthcare, media and telecom, financial institutions, real estate and gaming. BAS also does a significant amount of work for Financial Sponsors, or private equity firms, often financing leveraged transactions. Following the strategy of Goldman Sachs, the firm lacks a standalone mergers and acquisitions department, instead employing mergers and acquisitions senior bankers throughout the industry coverage groups. The firm is registered as a broker/dealer with the SEC, is a member of the NYSE, and the NASD. The use of Banc in the BAS's name is indicative of the fact that the company is not a bank, and their deposits and other holdings are not insured by the FDIC. | Corporate Officer/Principal | - |
Ausbildung von Stephen From
University of Western Ontario | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
KIORA PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Banc of America Securities LLC
Banc of America Securities LLC Investment Banks/BrokersFinance Headquartered in Charlotte, North Carolina, Banc of America Securities (BAS) is the investment banking subsidiary of Bank of America Corp (NYSE: BAC). The firm provides both the domestic and international equity and investment banking markets, and pursues a strategy pioneered by Citigroup that combines corporate lending with investment banking advice and services. They provide high-yield debt underwriting and leveraged finance, in addition to industry coverage groups such as healthcare, media and telecom, financial institutions, real estate and gaming. BAS also does a significant amount of work for Financial Sponsors, or private equity firms, often financing leveraged transactions. Following the strategy of Goldman Sachs, the firm lacks a standalone mergers and acquisitions department, instead employing mergers and acquisitions senior bankers throughout the industry coverage groups. The firm is registered as a broker/dealer with the SEC, is a member of the NYSE, and the NASD. The use of Banc in the BAS's name is indicative of the fact that the company is not a bank, and their deposits and other holdings are not insured by the FDIC. | Finance |
Aruna Bio, Inc.
Aruna Bio, Inc. Medical/Nursing ServicesHealth Services Aruna Bio, Inc. manufactures and provides neural stem cells. Its products include neuronet pure human neurons screening kit, neuronet pure human neurons discovery kit, co-culture kit hastropro-neuronet, hastropro human astrocytes kit and motor neurons GFP+htscreening kit. The company was founded by James Stice and Steven L. Stice in 2003 and is headquartered in Athens, GA. | Health Services |
Centelion SAS | |
EyeGate Pharma SAS
EyeGate Pharma SAS Pharmaceuticals: MajorHealth Technology Part of Kiora Pharmaceuticals, Inc., EyeGate Pharma SAS is a clinical-stage specialty pharmaceutical company based in Paris, France. EyeGate's products include pp-001, a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of dihydroorotate dehydrogenase (“dhodh”) with picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with dhodh inhibitors. The French company is also developing ocular bandage gel (“ obg ”), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. OBG, with unique properties that help hydrate and protect the ocular surface, is in clinical evaluation for patients undergoing photorefractive keratectomy (“prk”) surgery for corneal wound repair after refractive surgery and patients with persistent corneal epithelial defects. Founded in 1998, the private company develops and commercializes products for treating ophthalmic diseases. | Health Technology |